BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 25687203)

  • 1. Incidence, management, and course of cancer in patients with inflammatory bowel disease.
    Algaba A; Guerra I; Marín-Jiménez I; Quintanilla E; López-Serrano P; García-Sánchez MC; Casis B; Taxonera C; Moral I; Chaparro M; Martín-Rodríguez D; Martín-Arranz MD; Manceñido N; Menchén L; López-Sanromán A; Castaño Á; Bermejo F
    J Crohns Colitis; 2015 Apr; 9(4):326-33. PubMed ID: 25687203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
    Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents.
    Axelrad J; Bernheim O; Colombel JF; Malerba S; Ananthakrishnan A; Yajnik V; Hoffman G; Agrawal M; Lukin D; Desai A; McEachern E; Bosworth B; Scherl E; Reyes A; Zaidi H; Mudireddy P; DiCaprio D; Sultan K; Korelitz B; Wang E; Williams R; Chen L; Katz S; Itzkowitz S;
    Clin Gastroenterol Hepatol; 2016 Jan; 14(1):58-64. PubMed ID: 26247164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
    Peyrin-Biroulet L; Khosrotehrani K; Carrat F; Bouvier AM; Chevaux JB; Simon T; Carbonnel F; Colombel JF; Dupas JL; Godeberge P; Hugot JP; Lémann M; Nahon S; Sabaté JM; Tucat G; Beaugerie L;
    Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma--challenges in management.
    Lee J; Clarke K
    Int J Colorectal Dis; 2015 Dec; 30(12):1595-602. PubMed ID: 26349591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain.
    Gómez-García M; Cabello-Tapia MJ; Sánchez-Capilla AD; De Teresa-Galván J; Redondo-Cerezo E
    World J Gastroenterol; 2013 Aug; 19(30):4877-86. PubMed ID: 23946592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study.
    Rungoe C; Basit S; Ranthe MF; Wohlfahrt J; Langholz E; Jess T
    Gut; 2013 May; 62(5):689-94. PubMed ID: 22961677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
    McKenna MR; Stobaugh DJ; Deepak P
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males.
    Söderlund S; Granath F; Broström O; Karlén P; Löfberg R; Ekbom A; Askling J
    Gastroenterology; 2010 May; 138(5):1697-703. PubMed ID: 20167217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracolonic Cancer in Inflammatory Bowel Disease: Data from the GETECCU Eneida Registry.
    Chaparro M; Ramas M; Benítez JM; López-García A; Juan A; Guardiola J; Mínguez M; Calvet X; Márquez L; Fernández Salazar LI; Bujanda L; García C; Zabana Y; Lorente R; Barrio J; Hinojosa E; Iborra M; Cajal MD; Van Domselaar M; García-Sepulcre MF; Gomollón F; Piqueras M; Alcaín G; García-Sánchez V; Panés J; Domènech E; García-Esquinas E; Rodríguez-Artalejo F; Gisbert JP
    Am J Gastroenterol; 2017 Jul; 112(7):1135-1143. PubMed ID: 28534520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment.
    Wauters L; Billiet T; Papamichael K; Ballet V; Joniau S; Verschueren P; Silversmit G; Van Assche G; Vermeire S; Ferrante M
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):84-90. PubMed ID: 27603297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
    Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
    J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis.
    Singh S; Nagpal SJ; Murad MH; Yadav S; Kane SV; Pardi DS; Talwalkar JA; Loftus EV
    Clin Gastroenterol Hepatol; 2014 Feb; 12(2):210-8. PubMed ID: 23644389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III).
    Magro F; Peyrin-Biroulet L; Sokol H; Aldeger X; Costa A; Higgins PD; Joyce JC; Katsanos KH; Lopez A; de Xaxars TM; Toader E; Beaugerie L
    J Crohns Colitis; 2014 Jan; 8(1):31-44. PubMed ID: 23721759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.
    Kotlyar DS; Lewis JD; Beaugerie L; Tierney A; Brensinger CM; Gisbert JP; Loftus EV; Peyrin-Biroulet L; Blonski WC; Van Domselaar M; Chaparro M; Sandilya S; Bewtra M; Beigel F; Biancone L; Lichtenstein GR
    Clin Gastroenterol Hepatol; 2015 May; 13(5):847-58.e4; quiz e48-50. PubMed ID: 24879926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis.
    Jess T; Lopez A; Andersson M; Beaugerie L; Peyrin-Biroulet L
    Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1793-1800.e1. PubMed ID: 24907505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall and Comparative Risk of Herpes Zoster With Pharmacotherapy for Inflammatory Bowel Diseases: A Nationwide Cohort Study.
    Khan N; Patel D; Trivedi C; Shah Y; Lichtenstein G; Lewis J; Yang YX
    Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1919-1927.e3. PubMed ID: 29309905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study.
    Rungoe C; Simonsen J; Riis L; Frisch M; Langholz E; Jess T
    Clin Gastroenterol Hepatol; 2015 Apr; 13(4):693-700.e1. PubMed ID: 25086189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease.
    van Schaik FD; van Oijen MG; Smeets HM; van der Heijden GJ; Siersema PD; Oldenburg B
    Gut; 2012 Feb; 61(2):235-40. PubMed ID: 21602529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease.
    Singh H; Nugent Z; Demers AA; Bernstein CN
    Gastroenterology; 2011 Nov; 141(5):1612-20. PubMed ID: 21806945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.